In this medical education podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center of Thoracic Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, USA) provide pathologist and medical oncologist perspectives about the detection and treatment of TRK fusion-positive lung cancers.
They discuss a number of techniques and strategies to identify this rare fusion in lung cancer patients, before going on to summarise the robust efficacy and safety data for both entrectinib and larotrectinib. Prof. Rolfo briefly covers second-generation therapies in clinical development and describes how liquid biopsy is emerging as a new technique not only to identify but also monitor patients. They conclude by stressing the importance of the collaboration and communication between pathologists and oncologists to test for and identify TRK fusion-positive lung cancer patients.
Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the...
Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro,...
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic...